 The GSK compound, which has now a complicated name like Belantanathenathodotin, we call it sometimes Bellamuff to make it easier, is first in glass, a very novel immunocontrogate. So it targets as an antibody the BCMA, the B-cell maturation antigen, which is expressed on a high level on myeloma cells, and not really somewhere else. And it has conjugated to the antibody a toxin or instatine cell, it's a combined modality. The antibody recognizes the myeloma cell, the toxin is implemented in the cell and can lead then to the, can induce the cell death. And this is a very unique construct with this drug. Dream 3 will be the European approval trial for Belantanathodotin, it is a randomized trial again 2-to-1 in favor for Belantanath, where Belantanathodotin is given as a single agent every 3 weeks, 1 hour in fusion, and is compared to the combination of pulmalidomide and dexametazone, which is a standard of care in Europe for relapsing refractory myeloma patients after at least 2 prior lines and having had lanolidomide and proteazone inhibited. It is expected that the single agent Belantanathodotin is superior, for this the trial is powered. As the early trials showed a very encouraging response rate of 60% partial remissions and more in highly and heavily pre-treated patients with the median progression for survival of 12 months in the first trial are conducted. So we are expecting superiority and a new standard of care for relapsing refractory patients. The quality of life will be measured with the regular forms where patients ask different questions in different areas like it is established for approval trials. Sometimes you think when you are looking on this questionnaire or you doubt if they capture really everything, but in general when you then look over hundreds of patients it reflects very well how quality of life is during treatment and so these are highly validated questionnaires which were now used all over the approval trials and therefore also well comparable. This is a very unique side effect of this drug class, the blood version which the cause is a corneal ulceration due to the toxin which can be accumulated there and this can be handled with prophylaxis with eye drops and with therapeutic eye drops, but it affects around like one third of the patients in a significant manner and it's completely reversible what we currently know, but in fact some patients had to in the early trials had to interact or even to stop the medication, but we all learn together how to handle this and there are now well established protocols overall and it's a new toxicity we face here, but what we currently know is that we can manage it very well.